Arvinas (ARVN) Gains Despite $250M Stock Offering

Arvinas, Inc. (Nasdaq: ARVN) is trading 3.4% higher after-hours despite announcing an underwritten public offering of $250.0 million of its common stock. Shares rose 95% today on positive clinical data for its PROTAC protein degraders ARV-471 and ARV-110.

You May Also Be Interested In

• Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
• Apple Cuts Jobs in Siri, Vision Pro 3D Video and Gaming Teams - Bloomberg
• Uber fined $966 Million in the Netherlands for automating driver suspensions - Reuters